NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
7 Hills Pharma, LLC
Pfizer
Bristol-Myers Squibb
DEKA Biosciences
Bristol-Myers Squibb
Nektar Therapeutics
Bristol-Myers Squibb
Bristol-Myers Squibb
BioNTech SE
Celldex Therapeutics